Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05503511 · ClinicalTrials.gov registry record · Phase 1
Safety and Pharmacokinetic Study of NPT 2042 Soft-gelatin Capsules Administered Orally to Healthy Adult Subjects
A Phase 1 study, sponsored by NeuroPro Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 50
- Enrollment target
NCT05503511: Completed Phase 1 study, sponsored by NeuroPro Therapeutics.
NCT05503511 is a Phase 1 study that has completed, run by NeuroPro Therapeutics. The registered enrollment target is 50 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (17% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05503511, a Phase 1 study, has completed, sponsored by NeuroPro Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 50 participants
- Enrollment target
Study Summary
Study NPT 2042 CL 101 is a first in human (FIH) study to evaluate the safety and pharmacokinetics (PK) of single and repeated ascending doses of NPT 2042 in healthy adult male and female subjects.
Primary Outcome
Absolute values and change from baseline after a single dose or after 7 days of repeated dosing.
Interventions
- DRUG NPT 2042 (bumetanide analog) or Matching Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2022-10-20 |
| Est. Completion | 2023-03-30 |
| Phase | Phase 1 |
What the finished NCT05503511 record still lists
NCT05503511 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (17% lower).
The record links to 0 conditions, and to 1 intervention - of which NPT 2042 (bumetanide analog) or Matching Placebo is the first listed.
NCT05503511 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05503511 about?
NCT05503511 is a clinical study titled "Safety and Pharmacokinetic Study of NPT 2042 Soft-gelatin Capsules Administered Orally to Healthy Adult Subjects". Study NPT 2042 CL 101 is a first in human (FIH) study to evaluate the safety and pharmacokinetics (PK) of single and repeated ascending doses of NPT 2042 in healthy adult male and female subjects.
What is the current status of trial NCT05503511?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2022-10-20. Estimated completion is 2023-03-30.
What interventions are being tested in trial NCT05503511?
The interventions under investigation include: NPT 2042 (bumetanide analog) or Matching Placebo (DRUG).
Who is sponsoring clinical trial NCT05503511?
This trial is sponsored by NeuroPro Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05503511's enrollment target sits among peer trials
50 973rd of 2000 higher than 984 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI